Lung cancer drug shows promise against brain spread in Real-World review
NCT ID NCT07239102
First seen Nov 20, 2025 · Last updated May 17, 2026 · Updated 15 times
Summary
This study looked back at medical records of 300 people with a specific type of lung cancer (EGFR-positive non-small cell lung cancer) that had spread to the brain or spinal cord. All patients were treated with the drug firmonertinib. The goal was to see how long the drug kept the cancer from growing in the brain and to understand why some patients stop responding. This is an observational study, not a test of a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEPTOMENINGEAL METASTASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Li Xiaoyan
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.